



28 **Abstract**

29 **Rationale**

30 Bedaquiline is a novel antimycobacterial agent for drug-resistant tuberculosis (DR-TB) and is classified  
31 as a World Health Organization (WHO) Group A drug due to its excellent clinical efficacy, high  
32 bactericidal activity, and potent sterilizing effect. Baseline and treatment-emergent bedaquiline  
33 resistance have been described but prevalence and incidence have not been reported, leading to gaps  
34 in the knowledge required to design strategies to optimize MDR-TB clinical outcomes and prevent the  
35 amplification of bedaquiline resistance.

36

37 **Methods**

38 We performed a systematic review and meta-analysis to estimate the frequency of, and mutations  
39 associated with, baseline and acquired (treatment-emergent) bedaquiline resistance in clinical *Mtb*  
40 isolates. Pooled estimates of bedaquiline resistance were generated by proportional meta-analysis in R  
41 version 4.2.2 using dmetar, metafor and meta packages. Resistance associated variants associated with  
42 prevalent and incident bedaquiline resistance were identified.

43

44 **Results**

45 Data from 14 studies were included; 14 and 9 studies reported on pre-treatment and acquired  
46 bedaquiline resistance, respectively. The pooled prevalence of pre-treatment bedaquiline resistance  
47 was 2.4% (95% CI 1.7 – 3.5), with significant heterogeneity across all studies ( $I^2$  66%,  $p < 0.01$ ). The  
48 pooled prevalence of treatment-emergent bedaquiline resistance was 2.1% (95% CI 1.4 - 3.0), with no  
49 significant heterogeneity across the included studies ( $I^2$  0%,  $p = 0.97$ ).

50

51 **Discussion**

52 We found a concerning frequency of bedaquiline resistance present at baseline and acquired during  
53 treatment. Urgent strategies are required to mitigate further resistance to this crucial drug.

54

55

56

57 **Baseline and treatment-emergent bedaquiline resistance in drug-resistant tuberculosis:**  
58 **A systematic review and meta-analysis**

59

60 Bedaquiline is a novel antimycobacterial agent for drug-resistant tuberculosis (DR-TB) and is classified  
61 as a World Health Organization (WHO) Group A drug due to its excellent clinical efficacy, high  
62 bactericidal activity, and potent sterilizing effect.(1) The introduction of bedaquiline into treatment  
63 regimens has enabled short-course all-oral multidrug-resistant TB (MDR-TB) regimens and the  
64 shortening of drug-susceptible TB treatment.(2, 3)

65

66 Bedaquiline targets F<sub>1</sub>F<sub>0</sub>-ATP synthase to impair *Mycobacterium tuberculosis* (*Mtb*) ATP synthesis and  
67 exerts other incompletely characterized bactericidal effects.(4) Variants in the target *atpE* and *atpB*  
68 genes and off-target mutations in *mmpR5*, *mmpL5*, and *pepQ* have been associated with bedaquiline  
69 resistance.(5, 6) We performed a systematic review and meta-analysis to estimate the frequency of,  
70 and mutations associated with, baseline and acquired (treatment-emergent) bedaquiline resistance in  
71 clinical *Mtb* isolates.

72

73 The study protocol was registered in PROSPERO (CRD42022346547) and the PRISMA guidelines were  
74 followed for reporting of the review methods and findings. Systematic searches of MEDLINE/PubMed,  
75 Cochrane Central Register of Clinical Trials, and EMBASE were conducted through February 2023 for  
76 publications on phenotypic resistance of bedaquiline. We included studies which reported clinical *Mtb*  
77 isolates with bedaquiline resistance via minimum inhibitory concentration (MIC) values from patients  
78 with at least rifampicin-resistant TB. Given the suboptimal positive predictive value of resistance-  
79 associated variants for phenotypic resistance, our study only evaluated phenotypic resistance as  
80 defined by MIC thresholds. We excluded studies with MIC cutoffs inconsistent with WHO cutoffs, *in*  
81 *vitro* *Mtb* isolates not obtained from patients, or  $\leq 3$  patients/isolates. Phenotypic bedaquiline  
82 resistance was defined by critical concentrations of 1  $\mu$ g/ml by MGIT method or 0.25  $\mu$ g/ml by broth  
83 microdilution or 7H11 agar proportion method. Acquired bedaquiline resistance was defined as the  
84 absence of phenotypic resistance before treatment and demonstration of phenotypic resistance on at  
85 least one occasion during bedaquiline treatment (**Table S1**). Publication bias was evaluated using

86 funnel plots and methodological quality was assessed by the tool proposed by Hoy *et al.*(7) We  
87 performed a proportional meta-analysis in R version 4.2.2 using dmetar, metafor and meta packages.  
88 Paired MIC and resistance-associated variant (RAV) data were presented by scatterplots. Detailed  
89 methods are available in the Supplementary File.

90  
91 The systematic search identified 180 articles for assessment: 37 were duplicates, 47 did not meet  
92 inclusion criteria, and 82 were excluded because they were in vitro studies, review papers, case  
93 reports, used non-standardized MIC thresholds, did not distinguish between baseline and treatment-  
94 emergent resistance, contained overlapping data with another study, or had no retrievable full text  
95 (**Figure S1**). The remaining 14 studies were included, comprising four randomized controlled trials and  
96 10 cohort studies, emanating from five continents (**Table S2**). (5, 6, 8-19) In both baseline and during-  
97 treatment analyses there was evidence of significant positive publication bias. For the baseline  
98 analysis, 13 studies were rated as low risk of bias, and one study as moderate risk of bias. For the  
99 during-treatment analysis, three studies were rated as low risk of bias, and six studies as moderate risk  
100 of bias (**Tables S3 and S4**).

101  
102 Fourteen studies, with a pooled sample of 9975 isolates, contributed to the estimate of baseline  
103 bedaquiline resistance. Nine studies, with a pooled sample of 1912 isolates, contributed to the  
104 estimate of treatment-emergent bedaquiline resistance. The pooled prevalence of baseline  
105 bedaquiline resistance was 2.4% (95% CI 1.7 – 3.5), with significant heterogeneity across all studies ( $I^2$   
106 66%,  $p < 0.01$ ) (**Figure 1, Panel A**). The pooled prevalence of treatment-emergent bedaquiline resistance  
107 was 2.1% (95% CI 1.4 - 3.0), with no significant heterogeneity across the included studies ( $I^2$  0%,  
108  $p = 0.97$ ) (**Figure 1, Panel B**). In the sensitivity analyses, no between-group differences were seen based  
109 on the quality of the studies (low versus moderate risk of bias).

110  
111 We identified 141 RAVs across all isolates in the included studies, comprising 71 unique RAVs at 58  
112 unique sites. Four RAVs were mapped to the promoter region of the Mtb genome, 19 were mapped to  
113 the dimerization domains, and 42 were mapped to the DNA binding region. The complete list of RAVs  
114 and associated MICs is presented by scatterplot (**Figure 1, Panels C and D**). Treatment-emergent RAVs

115 were significantly more likely to be associated with phenotypic resistance than pre-treatment RAVs  
116 [21/35 (60.0%, 95% CI 42.9 – 77.7) vs 24/97 (24.7%, 95% CI 15.8 – 33.7)].

117 The high degree of heterogeneity and publication bias suggests that our pooled estimate of baseline  
118 bedaquiline resistance (2.4%, 95% CI 1.7 – 3.5) may overestimate the true prevalence in clinical  
119 settings. However, the two included studies which involved comprehensive national surveillance of all  
120 patients initiating treatment for MDR-TB produced reliable estimates of pre-treatment bedaquiline  
121 resistance of 3.2% and 3.6% in Germany and South Africa, respectively.(8, 17) These levels of pre-  
122 treatment bedaquiline resistance likely reflect high rates of person-to-person community transmission  
123 of bedaquiline-resistant TB.

124

125 We found a concerning pooled prevalence of acquired bedaquiline resistance during treatment – 2.1%  
126 (95%CI 1.4 –3.0%). Our estimate is concordant with a previous systematic review which reported a  
127 frequency of phenotypic acquired bedaquiline resistance of 2.2%.(20) The low heterogeneity among  
128 included studies reflects the systematic evaluation of serial cultures from all patients treated for MDR-  
129 TB, ranging from weekly to alternate months until culture conversion. This approach avoided the  
130 spuriously high estimates of acquired bedaquiline resistance reported in studies that only performed  
131 serial phenotypic DST in patients with evidence of treatment failure.(21)

132

133 *As mmpR5 (Rv0678)* mutations are associated with cross-resistance to clofazimine and bedaquiline,  
134 prior exposure to clofazimine may have contributed to the high levels of pre-treatment bedaquiline  
135 resistance identified in settings with limited prior use of bedaquiline. As a WHO group B drug,  
136 clofazimine has been increasingly used as part of shortened MDR-TB regimens globally. Bedaquiline  
137 has a relatively long elimination half-life, estimated at around 5.5 months, rendering it particularly  
138 vulnerable to acquired resistance when treatment is interrupted. For this reason, high levels of  
139 adherence support, patient tracking, and robust novel treatment regimens with a high barrier to  
140 resistance are necessary to mitigate the risk of acquired resistance. In addition, bedaquiline exhibits  
141 sub-optimal penetration into caseous necrotic lesions exposing it to intralesional PK-PD mismatch.(22)  
142 Few MDR-TB drugs offer adequate protection against bedaquiline resistance, which is an increasingly  
143 important consideration when constructing an MDR-TB regimen.(8)

144 Bedaquiline received US Food and Drug Administration accelerated approval in 2012 and by 2014 – the  
145 first case of bedaquiline-resistant TB was reported in a Tibetan refugee following treatment with a  
146 bedaquiline-containing regimen.(23) Between 2015 and 2019, there were an estimated 300 cases of  
147 bedaquiline-resistant TB cases in South Africa alone.(17) We are reminded that the prevalence of  
148 rifampicin resistance was initially ~12 per 1000 patients shortly after roll out of rifampicin, but  
149 amplified to ~300 per 1000 patients currently.(24, 25) A Markov decision modelling exercise estimated  
150 the prevalence of bedaquiline resistance increasing to 588 per 1000 patients with more widespread  
151 bedaquiline rollout.(26)

152

153 As we prepare for the mass rollout of bedaquiline-containing short-course regimens for the treatment  
154 of MDR-TB, National TB Programmes will require substantial strengthening to avoid escalating levels of  
155 bedaquiline resistance, ensuing surges in treatment failure and relapse, a growing dependence on  
156 complex salvage regimens, and treatment destitution. Central to reducing the threat of bedaquiline-  
157 resistant TB epidemic is the need for a rapid diagnostic test to detect bedaquiline resistance. Research  
158 to better understand the genetics of resistance as well as investment in rapid phenotypic methods  
159 such as microscopic observation of drug susceptibility and reporter mycobacteriophages may be  
160 required. To date, the development of a rapid molecular diagnostic assay has been severely  
161 constrained by the poor phenotypic-genotypic concordance of resistance profiling for bedaquiline. In  
162 parallel, as bedaquiline-based regimens are implemented, national and supra-national bedaquiline  
163 resistance surveillance activities must be escalated as a critical early warning system.

164

#### 165 **Competing interests**

166 The authors declare that they have no competing interests.

167

#### 168 **Data availability**

169 Materials related to this review are available from the authors upon request.

170

171

172

## 173 References

- 174 1. Olayanju O, Limberis J, Esmail A, Oelofse S, Gina P, Pietersen E, et al. Long-term bedaquiline-  
175 related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa.  
176 *The European respiratory journal*. 2018;51(5).
- 177 2. World Health Organisation. Rapid communication: key changes to the treatment of drug-  
178 resistant tuberculosis. Geneva; 2022.
- 179 3. Paton NI, Cousins C, Suresh C, Burhan E, Chew KL, Dalay VB, et al. Treatment Strategy for  
180 Rifampin-Susceptible Tuberculosis. *The New England journal of medicine*. 2023;388(10):873-87.
- 181 4. Mackenzie JS, Lamprecht DA, Asmal R, Adamson JH, Borah K, Beste DJV, et al. Bedaquiline  
182 reprograms central metabolism to reveal glycolytic vulnerability in *Mycobacterium tuberculosis*.  
183 *Nature communications*. 2020;11(1):6092.
- 184 5. Nimmo C, Millard J, van Dorp L, Brien K, Moodley S, Wolf A, et al. Population-level emergence  
185 of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant  
186 tuberculosis in southern Africa: a phenotypic and phylogenetic analysis. *Lancet Microbe*.  
187 2020;1(4):e165-e74.
- 188 6. Kaniga K, Hasan R, Jou R, Vasiliauskienė E, Chuchottaworn C, Ismail N, et al. Bedaquiline Drug  
189 Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective  
190 In Vitro Surveillance Study of Bedaquiline and Other Second-Line Drug Susceptibility Testing in MDR-TB  
191 Isolates. *J Clin Microbiol*. 2022;60(1):e0291920.
- 192 7. Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, et al. Assessing risk of bias in prevalence  
193 studies: modification of an existing tool and evidence of interrater agreement. *Journal of clinical*  
194 *epidemiology*. 2012;65(9):934-9.
- 195 8. Andres S, Merker M, Heyckendorf J, Kalsdorf B, Rumetshofer R, Indra A, et al. Bedaquiline-  
196 Resistant Tuberculosis: Dark Clouds on the Horizon. *American journal of respiratory and critical care*  
197 *medicine*. 2020;201(12):1564-8.
- 198 9. Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al. Treatment of Highly  
199 Drug-Resistant Pulmonary Tuberculosis. *The New England journal of medicine*. 2020;382(10):893-902.
- 200 10. Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, Mahanyele R, et al. Randomized pilot  
201 trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term  
202 outcome, tolerability, and effect on emergence of drug resistance. *Antimicrobial agents and*  
203 *chemotherapy*. 2012;56(6):3271-6.
- 204 11. Guglielmetti L, Jaspard M, Le Dû D, Lachâtre M, Marigot-Outtandy D, Bernard C, et al. Long-  
205 term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. *The*  
206 *European respiratory journal*. 2017;49(3).
- 207 12. Ismail NA, Omar SV, Joseph L, Govender N, Blows L, Ismail F, et al. Defining Bedaquiline  
208 Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective  
209 Cohort Study. *EBioMedicine*. 2018;28:136-42.
- 210 13. Kempker RR, Mikiashvili L, Zhao Y, Benkeser D, Barbakadze K, Bablishvili N, et al. Clinical  
211 Outcomes Among Patients With Drug-resistant Tuberculosis Receiving Bedaquiline- or Delamanid-  
212 Containing Regimens. *Clinical infectious diseases : an official publication of the Infectious Diseases*  
213 *Society of America*. 2020;71(9):2336-44.
- 214 14. Liu Y, Gao M, Du J, Wang L, Gao J, Shu W, et al. Reduced Susceptibility of *Mycobacterium*  
215 *tuberculosis* to Bedaquiline During Antituberculosis Treatment and Its Correlation With Clinical

- 216 Outcomes in China. *Clinical infectious diseases : an official publication of the Infectious Diseases*  
217 *Society of America*. 2021;73(9):e3391-e7.
- 218 15. Veziris N, Bernard C, Guglielmetti L, Le Du D, Marigot-Outtandy D, Jaspard M, et al. Rapid  
219 emergence of *Mycobacterium tuberculosis* bedaquiline resistance: lessons to avoid repeating past  
220 errors. *The European respiratory journal*. 2017;49(3).
- 221 16. Villellas C, Coeck N, Meehan CJ, Lounis N, de Jong B, Rigouts L, et al. Unexpected high  
222 prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use  
223 of clofazimine or bedaquiline. *The Journal of antimicrobial chemotherapy*. 2017;72(3):684-90.
- 224 17. Ismail NA, Omar SV, Moultrie H, Bhyat Z, Conradie F, Enwerem M, et al. Assessment of  
225 epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in  
226 patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study. *The*  
227 *Lancet infectious diseases*. 2022;22(4):496-506.
- 228 18. Conradie F, Bagdasaryan TR, Borisov S, Howell P, Mikiashvili L, Ngubane N, et al. Bedaquiline-  
229 Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis. *The New England journal of medicine*.  
230 2022;387(9):810-23.
- 231 19. Wu SH, Chan HH, Hsiao HC, Jou R. Primary Bedaquiline Resistance Among Cases of Drug-  
232 Resistant Tuberculosis in Taiwan. *Frontiers in microbiology*. 2021;12:754249.
- 233 20. Mallick JS, Nair P, Abbew ET, Van Deun A, Decroo T. Acquired bedaquiline resistance during the  
234 treatment of drug-resistant tuberculosis: a systematic review. *JAC Antimicrob Resist*.  
235 2022;4(2):dlac029.
- 236 21. Ghodousi A, Rizvi AH, Baloch AQ, Ghafoor A, Khanzada FM, Qadir M, et al. Acquisition of Cross-  
237 Resistance to Bedaquiline and Clofazimine following Treatment for Tuberculosis in Pakistan.  
238 *Antimicrobial agents and chemotherapy*. 2019;63(9).
- 239 22. Sarathy JP, Zuccotto F, Hsinpin H, Sandberg L, Via LE, Marriner GA, et al. Prediction of Drug  
240 Penetration in Tuberculosis Lesions. *ACS Infect Dis*. 2016;2(8):552-63.
- 241 23. Somoskovi A, Bruderer V, Homke R, Bloemberg GV, Bottger EC. A mutation associated with  
242 clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment. *The*  
243 *European respiratory journal*. 2015;45(2):554-7.
- 244 24. Loutet MG, Davidson JA, Brown T, Dedicoat M, Thomas HL, Lalor MK. Acquired Resistance to  
245 Antituberculosis Drugs in England, Wales, and Northern Ireland, 2000-2015. *Emerging infectious*  
246 *diseases*. 2018;24(3):524-33.
- 247 25. Stottmeier KD. Emergence of rifampin-resistant *Mycobacterium tuberculosis* in Massachusetts.  
248 *The Journal of infectious diseases*. 1976;133(1):88-90.
- 249 26. Kunkel A, Cobelens FG, Cohen T. Tradeoffs in Introduction Policies for the Anti-Tuberculosis  
250 Drug Bedaquiline: A Model-Based Analysis. *PLoS medicine*. 2016;13(10):e1002142.
- 251

252 **Figure 1.** Pooled prevalence of baseline (**Panel A**) and treatment-emergent (**Panel B**) bedaquiline  
253 resistance in patients with drug-resistant TB. Baseline (**Panel C**) and treatment-emergent (**Panel D**)  
254 resistance-associated variants and associated minimum inhibitory concentrations. Solid black lines  
255 represent intermediate or resistant MICs, dashed lines represent susceptible MICs, and dotted lines  
256 are RAVs that are associated with both susceptible and intermediate/resistant MICs.



